Kimberly Smith, ViiV R&D chief (ViiV Healthcare)

GSK and Vi­iV score break­through ther­a­py des­ig­na­tion in HIV pre­ven­tion, as Tru­va­da show­down draws near­er

A lit­tle less than a week af­ter beef­ing up the da­ta pack­age it plans to take to the FDA for the ex­per­i­men­tal HIV drug cabote­gravir, GSK-owned Vi­iV Health­care has re­ceived good news on the med­i­cine’s prospects.

Reg­u­la­tors des­ig­nat­ed cabote­gravir as a break­through ther­a­py for pre­ven­ta­tive HIV treat­ment, the com­pa­ny an­nounced Tues­day af­ter­noon, set­ting up a show­down with Gilead’s Tru­va­da. Vi­iV R&D chief Kim­ber­ly Smith said it like­ly sets up an NDA sub­mis­sion in the first half of next year, with the hope of launch­ing the drug in ear­ly 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.